VEGF and angiopoietins in diabetic glomerulopathy: How far for a new treatment?

被引：43

作者：

Dei Cas, Alessandra ^{[1
]}

Gnudi, Luigi ^{[2
]}

机构：

[1] Univ Parma, Dept Internal Med & Biomed Sci, I-43100 Parma, Italy

[2] Kings Coll London, Div Cardiovasc, London WC2R 2LS, England

来源：

METABOLISM-CLINICAL AND EXPERIMENTAL | 2012年 / 61卷 / 12期

关键词：

Diabetic nephropathy; Vascular endothelial growth factor; Angiopoietins; Therapy; ENDOTHELIAL GROWTH-FACTOR; KIDNEY-DISEASE; NEPHROTIC SYNDROME; RENAL EXPRESSION; HUMAN PODOCYTES; FACTOR RECEPTOR; A EXPRESSION; EARLY-STAGE; IN-VIVO; NEPHROPATHY;

D O I：

10.1016/j.metabol.2012.04.004

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Diabetic nephropathy (DN) is the major cause of end-stage renal disease in western countries and its prevalence continues to increase (United States Renal Data System 2010, http://www.usrds.org/). Treatments currently utilised for DN provide only partial renoprotection, hence the need to identify new targets for therapeutic intervention. Metabolic and haemodynamic abnormalities have been implicated in the pathogenesis of DN, triggering the activation of intracellular signaling molecules that lead to the dysregulation of vascular growth factors and cytokines, such as vascular endothelial growth factor (VEGF) and angiopoietins, important players in the functional and structural regulation of the glomerular filtration barrier. This review focuses on the importance of VEGF-A and angiopoietins in kidney physiology and in the diabetic kidney, exploring their potential therapeutic role in the prevention and delay of diabetic glomerulopathy. (C) 2012 Elsevier Inc. All rights reserved.

引用

页码：1666 / 1673

页数：8

共 77 条

[51] End-stage renal failure in type 2 diabetes:: A medical catastrophe of worldwide dimensions [J].

Ritz, E ;

Rychlík, I ;

Locatelli, F ;

Halimi, S .

AMERICAN JOURNAL OF KIDNEY DISEASES, 1999, 34 (05) :795-808

[52] Temporal renal expression of angiogenic growth factors and their receptors in experimental diabetes: role of the renin-angiotensin system [J].

Rizkalla, B ;

Forbes, JM ;

Cao, Z ;

Boner, G ;

Cooper, ME .

JOURNAL OF HYPERTENSION, 2005, 23 (01) :153-164

[53] Coexpression of neuropilin-1, Flk1, and VEGF164 in developing and mature mouse kidney glomeruli [J].

Robert, B ;

Zhao, XM ;

Abrahamson, DR .

AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY, 2000, 279 (02) :F275-F282

[54] Angiopoietin-1 alters microvascular permeability coefficients in vivo via modification of endothelial glycocalyx [J].

Salmon, Andrew H. J. ;

Neal, Christopher R. ;

Sage, Leslie M. ;

Glass, Catherine A. ;

Harper, Steven J. ;

Bates, David O. .

CARDIOVASCULAR RESEARCH, 2009, 83 (01) :24-33

[55] Increased vascular endothelial growth factor mRNA expression in the heart of streptozotocin-induced diabetic rats [J].

Sasso, FC ;

Carbonara, O ;

Persico, E ;

D'Ambrosio, R ;

Coppola, L ;

Nasti, R ;

Campana, B ;

Moschella, S ;

Torella, R ;

Cozzolino, D .

METABOLISM-CLINICAL AND EXPERIMENTAL, 2003, 52 (06) :675-678

[56] What is the mechanism of microalbuminuria in diabetes: a role for the glomerular endothelium? [J].

Satchell, S. C. ;

Tooke, J. E. .

DIABETOLOGIA, 2008, 51 (05) :714-725

[57] Angiopoietin 1 and vascular endothelial growth factor modulate human glomerular endothelial cell barrier properties [J].

Satchell, SC ;

Anderson, KL ;

Mathieson, PW .

JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2004, 15 (03) :566-574

[58]

Satchell SC, 2002, J AM SOC NEPHROL, V13, P544, DOI 10.1681/ASN.V132544

[59] Chronic renal diseases as a public health problem: Epidemiology, social, and economic implications [J].

Schieppati, A ;

Remuzzi, G .

KIDNEY INTERNATIONAL, 2005, 68 :S7-S10

[60] From hyperglycemia to diabetic kidney disease: The role of metabolic, hemodynamic, intracellular factors and growth factors/cytokines [J].

Schrijvers, BF ;

De Vriese, AS ;

Flyvbjerg, A .

ENDOCRINE REVIEWS, 2004, 25 (06) :971-1010

← 1 2 3 4 5 6 7 8 →